Mika Nabeno

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

Mika Nabeno, Fumihiko Akahoshi, Hiroyuki Kishida et al. · Biochemical and Biophysical Research Communications · 2013 · 297 citations

Drug Target, Biochemistry, Medicine +9

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Tomohiro Yoshida, Fumihiko Akahoshi, Hiroshi Sakashita et al. · Bioorganic & Medicinal Chemistry · 2012 · 148 citations · Full text

Biochemistry, Medicine, Rational Drug Design +7

Fused bicyclic heteroarylpiperazine-substituted l-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group

Tomohiro Yoshida, Fumihiko Akahoshi, Hiroshi Sakashita et al. · Bioorganic & Medicinal Chemistry · 2012 · 36 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Biochemistry +11

Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer’s disease

Kenji Fukunaga, Daiki Sakai, Kazutoshi Watanabe et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 31 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Alzheimer's Disease +11

Heterogeneous Environment of the S−H Group of Cys966 near the Flavin Chromophore in the LOV2 Domain of <i>Adiantum</i> Neochrome1

Yoshiaki Sato, Mika Nabeno, Tatsuya Iwata et al. · Biochemistry · 2007 · 27 citations